Other stockholders in the US-based antibody research company backed by Mitsubishi, include MPM BioVentures (17.72%), Sofinnova Ventures (11.86%), Alloy Ventures (11.19%), and Fidelity Ventures (9.71%).

US-based antibody research company KaloBios Pharmaceuticals, backed by corporate venturing units of Japan-based conglomerate Mitsubishi and US-based healthcare company Genzyme,  filed for its initial public offering with the SEC, in which it is seeking $60m.

Stockholders in the US-based company include MPM BioVentures (17.72%), Sofinnova Ventures (11.86%), Alloy Ventures (11.19%), and Fidelity Ventures (9.71%).

In 2008, the firm raised $12m in a series D round, with backing from corporate venturing units Genzyme Venturesand Mitsubishi UFJ Capital as well as…